Anthropic reports Claude drug-discovery results: 35,000 antibody designs, 89% faster document review

Anthropic's research post summarizes months of embedded work with six medicine developers. Concrete results include 35,000 antibody designs generated with Claude, CAR T-cell components redesigned to be 70% shorter than standard, and an 89% reduction in pharmaceutical documentation review time, from more than 25 hours to under 3. Generate Biomedicines' scientists have used a multi-agent system built with Claude Code since February 2026 to explore CAR biology designs. Anthropic also says it has started drug-discovery efforts of its own.

The work spans the pipeline, from molecular design to regulated clinical filings, supported by connectors for regulated industries. The announcement drew nearly 12K likes on X, and Endpoints framed it as Anthropic pitching an 'age of miracles' to biopharma.

Timing matters. It closely follows Anthropic's Form S-1 filing, and life sciences is a high-value vertical that strengthens the IPO story. OpenAI and Google DeepMind, through Isomorphic Labs, compete for the same customers.

Skepticism is warranted. r/biotech questioned whether real wet-lab validation is being sidelined, since antibody design counts are not clinical outcomes. On r/ClaudeAI, IPO debate focused on likely price increases and the 25% of revenue concentrated in five customers. Watch for peer-reviewed validation and named clinical milestones.